Geller J C, Cua M, Prieto L, Guo S D, Danilo P, Rosen M R
Department of Pharmacology and Pediatrics, College of Physicians and Surgeons of Columbia University, New York, 10032 USA.
Eur J Pharmacol. 1995 Dec 29;294(2-3):423-8. doi: 10.1016/0014-2999(95)00562-5.
We studied the role of alpha1-adrenoceptors in the modulation of ventricular tachycardia and fibrillation in chloralose-anesthetized dogs subjected to 30 min left anterior descending coronary artery occlusion. Study groups were control, and those treated with the alpha1-adrenoceptor-subtype blockers WB4101 (0.5 mg/kg i.v.) or chloroethylclonidine (1.9 mg/kg i.v.). For the first set of experiments all animals were in sinus rhythm and heart rate was slower in the chloroethylclonidine-pretreated animals than the WB4101-treated group (P < 0.05). During occlusion, ventricular tachycardia and ventricular fibrillation incidence did not differ among control, WB4101 or chloroethylclonidine (3 dogs with ventricular fibrillation in each group and 0, 2 and 3 dogs respectively with ventricular tachycardia), but ventricular premature depolarizations were significantly reduced by both interventions, and nonsustained ventricular tachycardia was suppressed by WB4101. In a second set of experiments, animals were atrially paced at a cycle length of 300 ms, and divided into control, WB4101-treated or chloroethylclonidine-treated, as above. Here, 9/10 chloroethylclonidine-treated animals developed ventricular tachycardia and fibrillation during occlusion, whereas only 4/10 controls and 4/10 WB4101-treated animals did so (P < 0.05). In conclusion, during sinus rhythm, both types of alpha1-adrenoceptor subtype blockade significantly suppressed ventricular premature depolarizations and neither affected ventricular tachycardia and fibrillation. In contrast, when heart rate was held constant, chloroethylclonidine clearly enhanced the occurrence of ventricular fibrillation during occlusion. These results suggest the alpha1-adrenoceptor subtype blocked by chloroethylclonidine, but not that blocked by WB4101, is capable of increasing the incidence of lethal arrhythmias that occur at rapid atrial rates during ischemia.
我们研究了α1-肾上腺素能受体在氯醛糖麻醉的犬左前降支冠状动脉闭塞30分钟期间对室性心动过速和颤动的调节作用。研究组包括对照组,以及用α1-肾上腺素能受体亚型阻滞剂WB4101(0.5mg/kg静脉注射)或氯乙可乐定(1.9mg/kg静脉注射)治疗的组。在第一组实验中,所有动物均处于窦性心律,氯乙可乐定预处理的动物心率比WB4101治疗组慢(P<0.05)。在闭塞期间,对照组、WB4101组或氯乙可乐定组的室性心动过速和室性颤动发生率无差异(每组3只犬发生室性颤动,分别有0、2和3只犬发生室性心动过速),但两种干预措施均显著减少了室性早搏,WB4101抑制了非持续性室性心动过速。在第二组实验中,动物以300ms的周期长度进行心房起搏,并如上分为对照组、WB4101治疗组或氯乙可乐定治疗组。在此,9/10的氯乙可乐定治疗动物在闭塞期间发生了室性心动过速和颤动,而只有4/10的对照组和4/10的WB4101治疗动物发生了这种情况(P<0.05)。总之,在窦性心律期间,两种类型的α1-肾上腺素能受体亚型阻滞均显著抑制室性早搏,且均不影响室性心动过速和颤动。相比之下,当心率保持恒定时,氯乙可乐定在闭塞期间明显增加了室性颤动的发生率。这些结果表明,氯乙可乐定阻断的α1-肾上腺素能受体亚型,而非WB4101阻断的亚型,能够增加缺血期间快速心房率时致死性心律失常的发生率。